Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

Stephen T Ward; Christopher J Weston; Emma Louise Shepherd; Rahul Hejmadi; Tariq Ismail; David H. Adams

doi:10.1186/s12885-016-2183-7

Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

Stephen T Ward^*, Christopher J Weston, Emma Louise Shepherd, Rahul Hejmadi, Tariq Ismail, David H. Adams

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3) promotes lymphocyte recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1 expression between CRC and healthy tissues.

METHODS: sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls. Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting.

RESULTS: The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group (399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC.

CONCLUSIONS: VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible reasons for this are discussed.

Original language	English
Article number	154
Number of pages	8
Journal	BMC Cancer
Volume	16
DOIs	https://doi.org/10.1186/s12885-016-2183-7
Publication status	Published - 24 Feb 2016

Bibliographical note

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Funding Information:
This article presents independent research funded by the National Institute for Health Research (NIHR), Medical Research Council (MR/J009962/1) and the Bowel Disease Research Foundation (BDRF).

Keywords

VAP-1,
AOC3
Colorectal Cancel
Tumor Markers

Access to Document

10.1186/s12885-016-2183-7Licence: CC BY 4.0

s12885-016-2183-7
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 1.4 MBLicence: CC BY 4.0

Cite this

@article{587a3d16253146309db7a2e5259c4ef9,

title = "Evaluation of serum and tissue levels of VAP-1 in colorectal cancer",

abstract = "BACKGROUND: The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3) promotes lymphocyte recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1 expression between CRC and healthy tissues.METHODS: sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls. Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting.RESULTS: The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group (399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC.CONCLUSIONS: VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible reasons for this are discussed.",

keywords = "VAP-1,, AOC3, Colorectal Cancel, Tumor Markers",

author = "Ward, {Stephen T} and Weston, {Christopher J} and Shepherd, {Emma Louise} and Rahul Hejmadi and Tariq Ismail and Adams, {David H.}",

note = "{\textcopyright} 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Funding Information: This article presents independent research funded by the National Institute for Health Research (NIHR), Medical Research Council (MR/J009962/1) and the Bowel Disease Research Foundation (BDRF).",

year = "2016",

month = feb,

day = "24",

doi = "10.1186/s12885-016-2183-7",

language = "English",

volume = "16",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

AU - Ward, Stephen T

AU - Weston, Christopher J

AU - Shepherd, Emma Louise

AU - Hejmadi, Rahul

AU - Ismail, Tariq

AU - Adams, David H.

N1 - © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Funding Information: This article presents independent research funded by the National Institute for Health Research (NIHR), Medical Research Council (MR/J009962/1) and the Bowel Disease Research Foundation (BDRF).

PY - 2016/2/24

Y1 - 2016/2/24

N2 - BACKGROUND: The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3) promotes lymphocyte recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1 expression between CRC and healthy tissues.METHODS: sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls. Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting.RESULTS: The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group (399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC.CONCLUSIONS: VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible reasons for this are discussed.

AB - BACKGROUND: The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3) promotes lymphocyte recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1 expression between CRC and healthy tissues.METHODS: sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls. Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting.RESULTS: The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group (399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC.CONCLUSIONS: VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible reasons for this are discussed.

KW - VAP-1,

KW - AOC3

KW - Colorectal Cancel

KW - Tumor Markers

UR - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2183-7#Ack1

U2 - 10.1186/s12885-016-2183-7

DO - 10.1186/s12885-016-2183-7

M3 - Article

C2 - 26912327

SN - 1471-2407

VL - 16

JO - BMC Cancer

JF - BMC Cancer

M1 - 154

ER -

Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this